vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and ICU MEDICAL INC (ICUI). Click either name above to swap in a different company.
ICU MEDICAL INC is the larger business by last-quarter revenue ($540.7M vs $395.6M, roughly 1.4× Dolby Laboratories, Inc.). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs -2.9%, a 26.9% gap on every dollar of revenue. On growth, Dolby Laboratories, Inc. posted the faster year-over-year revenue change (7.1% vs -14.1%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs -2.3%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
DLB vs ICUI — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $540.7M |
| Net Profit | $94.9M | $-15.7M |
| Gross Margin | 88.7% | 37.5% |
| Operating Margin | 28.5% | 1.0% |
| Net Margin | 24.0% | -2.9% |
| Revenue YoY | 7.1% | -14.1% |
| Net Profit YoY | 3.4% | 34.0% |
| EPS (diluted) | $0.99 | $-0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $540.7M | ||
| Q3 25 | $307.0M | $537.0M | ||
| Q2 25 | $315.5M | $548.9M | ||
| Q1 25 | $369.6M | $604.7M | ||
| Q4 24 | $357.0M | $629.8M | ||
| Q3 24 | $304.8M | $589.1M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $-15.7M | ||
| Q3 25 | $49.3M | $-3.4M | ||
| Q2 25 | $46.1M | $35.3M | ||
| Q1 25 | $91.8M | $-15.5M | ||
| Q4 24 | $67.8M | $-23.8M | ||
| Q3 24 | $58.6M | $-33.0M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | 37.5% | ||
| Q3 25 | 87.1% | 37.4% | ||
| Q2 25 | 86.1% | 37.9% | ||
| Q1 25 | 90.3% | 34.7% | ||
| Q4 24 | 88.6% | 36.1% | ||
| Q3 24 | 88.8% | 34.8% |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 1.0% | ||
| Q3 25 | 9.7% | 2.6% | ||
| Q2 25 | 15.1% | 1.9% | ||
| Q1 25 | 29.2% | 2.1% | ||
| Q4 24 | 22.4% | 6.0% | ||
| Q3 24 | 15.2% | 1.4% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | -2.9% | ||
| Q3 25 | 16.1% | -0.6% | ||
| Q2 25 | 14.6% | 6.4% | ||
| Q1 25 | 24.8% | -2.6% | ||
| Q4 24 | 19.0% | -3.8% | ||
| Q3 24 | 19.2% | -5.6% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $-0.63 | ||
| Q3 25 | $0.50 | $-0.14 | ||
| Q2 25 | $0.48 | $1.43 | ||
| Q1 25 | $0.94 | $-0.63 | ||
| Q4 24 | $0.70 | $-0.97 | ||
| Q3 24 | $0.59 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $2.1B |
| Total Assets | $3.2B | $4.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | — | ||
| Q3 25 | $702.6M | — | ||
| Q2 25 | $699.3M | — | ||
| Q1 25 | $626.6M | — | ||
| Q4 24 | $520.8M | $308.6M | ||
| Q3 24 | $482.0M | $312.5M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $2.1B | ||
| Q3 25 | $2.6B | $2.1B | ||
| Q2 25 | $2.6B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.5B | $2.0B |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $4.1B | ||
| Q3 25 | $3.2B | $4.1B | ||
| Q2 25 | $3.2B | $4.1B | ||
| Q1 25 | $3.2B | $4.2B | ||
| Q4 24 | $3.2B | $4.2B | ||
| Q3 24 | $3.1B | $4.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $60.6M |
| Free Cash FlowOCF − Capex | — | $36.0M |
| FCF MarginFCF / Revenue | — | 6.6% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | 1.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $91.8M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $60.6M | ||
| Q3 25 | $472.2M | $56.7M | ||
| Q2 25 | $67.7M | $11.2M | ||
| Q1 25 | $174.9M | $51.3M | ||
| Q4 24 | $106.8M | $40.2M | ||
| Q3 24 | $327.3M | $36.1M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $36.0M | ||
| Q3 25 | $435.9M | $27.6M | ||
| Q2 25 | $61.3M | $-8.5M | ||
| Q1 25 | $168.0M | $36.7M | ||
| Q4 24 | $100.0M | $16.1M | ||
| Q3 24 | $297.2M | $16.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 6.6% | ||
| Q3 25 | 142.0% | 5.1% | ||
| Q2 25 | 19.4% | -1.5% | ||
| Q1 25 | 45.5% | 6.1% | ||
| Q4 24 | 28.0% | 2.6% | ||
| Q3 24 | 97.5% | 2.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 4.6% | ||
| Q3 25 | 11.8% | 5.4% | ||
| Q2 25 | 2.0% | 3.6% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 1.9% | 3.8% | ||
| Q3 24 | 9.8% | 3.4% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | — | ||
| Q2 25 | 1.47× | 0.32× | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
